Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.

Autor: Umemura S; Department of Oncology, Georgetown University Medical Center, Washington, DC., Chen V; Department of Oncology, Georgetown University Medical Center, Washington, DC., Chahine JJ; Department of Oncology, Georgetown University Medical Center, Washington, DC., Kallakury B; Department of Oncology, Georgetown University Medical Center, Washington, DC., Zhao X; Department of Oncology, Georgetown University Medical Center, Washington, DC; Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Lung Cancer Center, China., Lee H; Department of Oncology, Georgetown University Medical Center, Washington, DC., Avantaggiati ML; Department of Oncology, Georgetown University Medical Center, Washington, DC., He Y; Sandra and Edward Meyer Cancer Center, Weill-Cornell Medicine, New York, NY., Wang C; Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Lung Cancer Center, China., Giaccone G; Department of Oncology, Georgetown University Medical Center, Washington, DC; Sandra and Edward Meyer Cancer Center, Weill-Cornell Medicine, New York, NY. Electronic address: gig4001@med.cornell.edu.
Jazyk: angličtina
Zdroj: Clinical lung cancer [Clin Lung Cancer] 2022 Mar; Vol. 23 (2), pp. e140-e147. Date of Electronic Publication: 2021 Jul 20.
DOI: 10.1016/j.cllc.2021.07.006
Abstrakt: Background: Key regulators of antitumor immunity such as arginase-1 and the adenosine pathway may have an important role in modulating the effect of immunotherapy. Here, we investigated the expression profile of these immune-related biomarkers in thymic epithelial tumors (TETs) and small cell lung cancer (SCLC), 2 solid tumors where immune checkpoint inhibitors have activity.
Materials and Methods: Immunohistochemical staining was performed using tissue microarrays of 123 TET (110 thymoma and 13 thymic carcinoma) and 125 SCLC cases. The expression profile of the following immune-related biomarkers was assessed: arginase-1, CD39, CD73, A2AR, PD-L2, and CD15. The expression profile was also correlated with clinical data.
Results: No sample was positive for arginase-1. In the adenosine pathway, the prevalence of positive staining for CD39, CD73, and A2AR was 4.9%, 2.5%, and 69.2%, in TETs and 0%, 1.7%, and 50.8%, in SCLC. The multivariate analysis showed that CD39 expression was significantly associated with worse disease related survival (hazard ratio [HR], 10.36; 95% confidence interval [CI]: 2.01-53.47; P= .005) and a shorter time-to progression (HR, 11.35; 95% CI, 2.11-61.23; P = .005) in TETs. Other biomarkers were not associated with disease related survival or time to progression in TETs. No biomarker was associated with survival in SCLC.
Conclusion: Arginase-1 was not detectable in TETs and SCLC. Expression of markers in the adenosine pathway were present in both TETs and SCLC. CD39 expression in tumor cells may identify subsets of patients with TETs with an unfavorable prognosis.
Competing Interests: Declaration of competing interest None.
(Copyright © 2021. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: